Nightingale Health

2,65

EUR

+1,92 %

HEALTH

First North Finland

Medical Equipment & Services

Health Care

4.531 følger denne virksomhed

+1,92%

-10,17%

-7,99%

-9,25%

-29,33%

+141,79%

+19,37%

-

-48,54%

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Markedsværdi

161,46 mio. EUR

Aktieomsætning

183,99 t EUR

P/E (adj.) (25e)

-9,52

EV/EBIT (adj.) (25e)

-6,09

P/B (25e)

2,34

EV/S (25e)

16,64

Udbytteafkast, % (25e)

-

Coverage

Anbefaling

Reducer

Kursmål

2.90 EUR

Opdateret

23.09.2024

Antti Luiro

Head of Nordic ER Development, Analyst

Latest research

Seneste analyse

Released: 23.09.2024

Seneste omfattende analyse

Released: 05.06.2023

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

6.3

2025

Delårsrapport Q2'25

Risiko

Business risk

Valuation risk

Lav

Høj

ViserAlle indholdstyper

Pressemeddelelse28.2.2025, 10.35

Nightingale Health to publish half-year report for July - December 2024 on 6 March 2025

Nightingale Health

Pressemeddelelse27.2.2025, 12.15

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health

Nightingale, Webcast, Q2'25

Videopræsentation6.3.2025, 12.00

Nightingale, Webcast, Q2'25

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Analytikerkommentar10.2.2025, 07.42 af

Nightingale's path to regulatory approval in the US is becoming clearer and progressing

As promised, Nightingale provided further information on plans to obtain regulatory approvals in the US on Friday.

Nightingale Health

Pressemeddelelse7.2.2025, 12.15

Nightingale Health announces its updated regulatory plan in the United States

Nightingale Health

Analytikerkommentar27.1.2025, 10.47 af

Nightingale Health enters Middle East collaboration

Nightingale has signed a pilot agreement and letter of intent with Enigma Genomics to use the company's Remote Health Check in a full-scale commercial operation for Enigma's clients in Saudi Arabia and the wider MENA region.

Nightingale Health

Pressemeddelelse27.1.2025, 07.00

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health

Analytikerkommentar24.1.2025, 07.46 af

Nightingale Health published new disease risk assessments

Nightingale announced that it has published two new disease risk assessments for its Health Check service: fatty liver disease and stroke.

Nightingale Health

Pressemeddelelse23.1.2025, 09.00

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Nightingale Health

Selskabsmeddelelse23.12.2024, 12.00

Conversion of Nightingale Health Plc's EMP shares to Series B shares

Nightingale Health

Selskabsmeddelelse20.12.2024, 15.35

Nightingale Health Plc - Managers' Transactions - Olli Karhi

Nightingale Health

Selskabsmeddelelse18.12.2024, 19.35

Nightingale Health Plc appoints Lago Kapital as liquidity provider

Nightingale Health

Selskabsmeddelelse13.12.2024, 13.50

Nightingale Health Plc: Subscription of Series B shares with option rights

Nightingale Health

Pressemeddelelse4.12.2024, 08.00

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Nightingale Health

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video2.12.2024, 14.00

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Analytikerkommentar29.11.2024, 11.06 af

Nightingale opens Singapore laboratory

According to the release, the opening of the laboratory will be celebrated on Monday, December 2, and the company expects the first healthcare samples to arrive at the laboratory during Q1/2025.

Nightingale Health

Pressemeddelelse29.11.2024, 09.30

Nightingale Health announces opening of its Singapore laboratory

Nightingale Health

Analytikerkommentar27.11.2024, 13.57 af

Nightingale explores transfer to Nasdaq Helsinki main list and OTC trading in the US

With the possible transfer and OTC cross-trading, the company aims, among other things, to improve the liquidity of the stock and to broaden its international shareholder base.

Nightingale Health

Selskabsmeddelelse27.11.2024, 12.20

Inside information: Nightingale Health is investigating the transfer of its B shares to the Main Market of Nasdaq Helsinki and adding the OTCQX market as an additional trading venue in the U.S.

Nightingale Health

Analytikerkommentar14.11.2024, 08.44 af

Nightingale completes necessary regulatory approvals in Singapore

According to the release, Nightingale's Singaporean subsidiary was granted ISO 13485:2016 certification, the final approval needed to begin operations in Singapore. The company says it is now ready to launch its blood testing service in Singapore before the end of the year.

Nightingale Health

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.